Evidence map›Paper›PMID 26629024›Full record

ArticleInternational journal of clinical and experimental medicine2015

The miR-149 rs2292832 T/C polymorphism may decrease digestive cancer susceptibility: an updated meta-analysis.

Lin Li, Tao Liu, Zuo Li, Lixin Zhang, Zhiqiang Zhang

Abstract read
In one paragraph

Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Association ofBiomedicines · 2023
    Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Lin LiDepartment of Rehabilitation, Shengjing Hospital of China Medical University Shenyang 110022, P. R. China.
Tao LiuDepartment of Urology, The First Hospital of China Medical University Shenyang 110001, P. R. China.
Zuo LiDepartment of Nephro-urology, Nagoya City University Graduate School of Medical Sciences Aichi 467-8601, Japan ; Department of Urology, The Second People's Hospital of Nanjing Medical University Changzhou 213003, P. R. China.
Lixin ZhangDepartment of Rehabilitation, Shengjing Hospital of China Medical University Shenyang 110022, P. R. China.
Zhiqiang ZhangDepartment of Rehabilitation, Shengjing Hospital of China Medical University Shenyang 110022, P. R. China.
China Medical University · CNFirst Hospital of China Medical University · CNNagoya City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRNAs) are a class of short non-coding, single stranded RNAs, which perform post-transcriptional regulatory functions as tumor suppressors or oncogenes. Single nucleotide polymorphisms (SNPs) in miRs genes are currently being identified for contributing to cancer risk, prognosis and survival, however, an association between miR-149 rs2292832 T/C SNP and cancer risk is uncertain. Therefore, we performed an updated meta-analysis of all currently publications to clarify this relationship. From PubMed and Chinese language (WanFang) databases, we located articles published up to June 1, 2015, obtaining 21 case-control studies from 20 different articles containing 8913 cases and 9944 controls based on search criteria for cancer susceptibility related to the miR-149 rs2292832 T/C SNP. Odds ratios (OR) and 95% confidence intervals (CI) revealed association strengths. There had no association between this SNP and whole cancer risk. At the same time, in several subgroups, also no association was found in ethnicity, sex and smoking status. Nevertheless, poorly significant association was detected in cancer type (Digestive cancer: OR = 0.90, 95% CI = 0.81-1.00, Pheterogeneity = 0.142 for CT vs. TT) and source of control (population-based: OR = 1.15, 95% CI = 1.00-1.32, Pheterogeneity = 0.427 for CC vs. CT+TT) subgroups. The miR-149 rs2292832 T/C SNP may poorly decrease digestive cancer risk. Studies with larger samples and gene-environment interactions are warranted to understand the role of miR-149 polymorphisms, especially rs2292832 T/C SNP, in whole cancer risk.

Indexed as

cancermeta-analysismiR-149polymorphismsexsmoking

Identifiers

PMID26629024
PMCPMC4658913
OpenAlexW2410865901

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.